The putative 116 kDa osteoclast specific vacuolar proton pump subunit has ubiquitous tissue distribution

Author： Scott B.B.   Chapman C.G.  

Publisher： Elsevier

ISSN： 0014-2999

Source： European Journal of Pharmacology, Vol.346, Iss.1, 1998-04, pp. : 3-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Use of Gastrointestinal Proton Pump Inhibitors to Regulate Osteoclast- Mediated Resorption of Calcium Phosphate Cements In Vivo

By  

Current Drug Delivery, Vol. 6, Iss. 2, 2009-04 ,pp. : 192-198

Bentham Science Publishers

Access to resources Recommend Favorite

Selective Inhibition of Osteoclast Vacuolar H+-ATPase

By  

Current Pharmaceutical Design, Vol. 8, Iss. 23, 2002-10 ,pp. : 2033-2048

Bentham Science Publishers

Access to resources Recommend Favorite

Proton-Pump Inhibitor Therapy in Patients with Gastro-Oesophageal Reflux Disease: Putative Mechanisms of Failure

By Fass Ronnie  

Drugs, Vol. 67, Iss. 11, 2007-01 ,pp. : 1521-1530

Adis International

Access to resources Recommend Favorite

Ral-GTPase interacts with the β1 subunit of Na+/K+-ATPase and is activated upon inhibition of the Na+/K+ pump

By Bhullar Rajinder P.   Clough Richard R.   Kanungo Juddy   Elsaraj Sherif M.   Grujic Ognjen  

Canadian Journal of Physiology and Pharmacology, Vol. 85, Iss. 3-4, 2007-03 ,pp. : 444-454

NRC Research Press

Access to resources Recommend Favorite

The osteoporosis and fracture risk for over the counter (OTC) proton pump inhibitors (PPIs) has been revoked by the FDA

By  

Reactions Weekly, Vol. 1, Iss. 1345, 2011-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite